sutimlimab-jome

FDA Drug Profile — Enjaymo

Drug Details

Generic Name
sutimlimab-jome
Brand Names
Enjaymo
Application Number
BLA761164
Sponsor
Recordati Rare Diseases, Inc.
NDC Codes
1
Dosage Forms
INJECTION, SOLUTION, CONCENTRATE
Routes
INTRAVENOUS
Active Ingredients
SUTIMLIMAB

Indications and Usage

1 INDICATIONS AND USAGE ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 ) Cold Agglutinin Disease ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).